Fenofibrate
Brand names: TriCor, Fenoglide, Lipofen · Generic available · Fibrate / PPAR-α agonist
What is Fenofibrate?
Fenofibrate is a prescription lipid-lowering medication belonging to the fibrate class of drugs. It has been used for decades to manage abnormal blood lipid levels, particularly very high triglycerides — a type of fat in the blood that, at extremely elevated levels, raises the risk of pancreatitis (inflammation of the pancreas) as well as contributing to cardiovascular disease risk over time.
The drug is available in several branded formulations (TriCor, Fenoglide, Lipofen) and as a widely available generic. Different formulations vary in how they are absorbed — some require food for proper absorption while others (micronized or nanoparticle formulations) do not — so it is important not to switch between formulations without guidance from a healthcare provider.
What is Fenofibrate Used For?
Fenofibrate is prescribed for two main lipid disorders, typically in adults whose blood fat levels remain dangerously elevated despite diet changes and exercise:
- Hypertriglyceridemia (very high triglycerides): Fenofibrate can dramatically reduce triglyceride levels — sometimes by 40–60%. This is especially important when triglycerides are severely elevated, as acute pancreatitis becomes a serious risk above certain thresholds.
- Mixed dyslipidemia: A combination of high triglycerides and low HDL ("good") cholesterol, often seen alongside conditions like metabolic syndrome or type 2 diabetes. Fenofibrate addresses both components of this lipid pattern.
- Adjunct to statin therapy: Sometimes added to a statin when triglycerides remain high or HDL remains low despite adequate LDL control, though this combination requires careful monitoring for muscle toxicity.
- Reducing small dense LDL: Fenofibrate shifts the LDL particle distribution toward larger, less atherogenic particles, which may confer additional cardiovascular benefit beyond what triglyceride numbers alone suggest.
How Does Fenofibrate Work?
Fenofibrate is a prodrug — meaning the body converts it to its active form, fenofibric acid, after ingestion. Fenofibric acid works by binding to and activating a nuclear receptor called PPAR-alpha (peroxisome proliferator-activated receptor alpha), which acts as a molecular switch regulating fat metabolism genes throughout the body, primarily in the liver and skeletal muscle.
When PPAR-alpha is activated, several important metabolic changes happen simultaneously: the production of lipoprotein lipase (an enzyme that breaks down triglyceride-carrying VLDL particles in the blood) increases significantly; the liver produces less of the VLDL particles themselves; and the production of apolipoprotein C-III, a protein that normally inhibits lipoprotein lipase, is reduced. The net result is a rapid and substantial fall in circulating triglycerides. At the same time, PPAR-alpha activation increases the production of apolipoprotein A-I and A-II — the major protein components of HDL — which raises HDL cholesterol levels and can improve reverse cholesterol transport.
Side Effects
Common Side Effects
- Gastrointestinal upset: nausea, abdominal pain, diarrhea, or constipation
- Headache
- Back pain and musculoskeletal discomfort
- Mild, asymptomatic elevations in liver enzymes (ALT, AST) — usually reversible on stopping the drug
- Mild increase in serum creatinine (a kidney marker) — usually not clinically significant but should be monitored
- Runny nose or respiratory symptoms
Serious Side Effects
- Myopathy and rhabdomyolysis: Muscle pain, tenderness, weakness, or dark (cola-colored) urine may indicate breakdown of muscle tissue. This risk is significantly increased when fenofibrate is combined with a statin medication. Report any unexplained muscle symptoms to your prescriber immediately.
- Hepatotoxicity (liver damage): Severe liver enzyme elevations or signs of liver failure (jaundice, dark urine, severe abdominal pain, unusual fatigue). Liver function tests are typically monitored periodically during treatment.
- Cholelithiasis (gallstones): Fenofibrate increases cholesterol excretion into bile, which can promote gallstone formation. Symptoms include right upper abdominal pain, especially after fatty meals.
- Pancreatitis: Paradoxically, although fenofibrate is used to prevent pancreatitis from very high triglycerides, it can rarely cause pancreatitis itself.
- Severe hypersensitivity reactions: Rash, hives, swelling, or difficulty breathing require immediate medical evaluation.
Drug Interactions
Fenofibrate has several clinically important interactions. Always provide your prescriber and pharmacist with a complete list of all medications, supplements, and herbal products you are taking.
| Drug / Drug Class | Interaction Type | Effect & What to Do |
|---|---|---|
| Statins (atorvastatin, rosuvastatin, simvastatin) | Pharmacodynamic (additive) | Increased risk of myopathy and rhabdomyolysis. Use with caution; monitor for muscle pain and weakness. Some statin–fibrate combinations carry higher risk than others. |
| Warfarin (Coumadin) | Pharmacodynamic (potentiation) | Fenofibrate enhances the blood-thinning effect of warfarin, raising INR and bleeding risk. INR must be monitored more frequently when fenofibrate is started, stopped, or changed in dose. |
| Cyclosporine | Pharmacokinetic | Cyclosporine can increase fenofibrate blood levels; also, fenofibrate may impair kidney function when combined with cyclosporine. Close monitoring required; use is generally avoided or carefully managed in transplant patients. |
| Bile acid sequestrants (cholestyramine, colesevelam) | Pharmacokinetic (reduced absorption) | Bile acid sequestrants bind fenofibrate in the gut, substantially reducing its absorption. Fenofibrate should be taken at least 1 hour before or 4–6 hours after a bile acid sequestrant. |
| Colchicine | Pharmacodynamic (additive) | Additive risk of myopathy. This combination should be used with caution and patients should be monitored for muscle symptoms. |
Who Should Not Take Fenofibrate?
- People with severe kidney disease (significantly reduced renal function) — fenofibrate can worsen kidney function
- People with severe liver disease or unexplained persistent liver enzyme elevations
- People with pre-existing gallbladder disease — fenofibrate increases the risk of gallstones
- Nursing (breastfeeding) mothers — fenofibrate passes into breast milk and its safety in infants is unknown
- People with a known hypersensitivity or allergy to fenofibrate or fenofibric acid
- Caution in pregnancy — benefit vs. risk must be carefully weighed with a prescriber
Frequently Asked Questions
What is fenofibrate used for?
Fenofibrate is used to treat very high triglyceride levels (hypertriglyceridemia) and mixed dyslipidemia — a pattern of high triglycerides combined with low HDL cholesterol. It is prescribed when dietary changes and exercise alone are not enough to control these abnormal blood fat levels. Severely elevated triglycerides can cause acute pancreatitis, making treatment important beyond just cardiovascular risk.
Can I take fenofibrate with a statin?
Fenofibrate is sometimes prescribed alongside a statin (such as atorvastatin or rosuvastatin) when someone has both high LDL cholesterol and high triglycerides. However, combining fibrates with statins increases the risk of myopathy (muscle damage) and, rarely, the serious condition rhabdomyolysis (severe muscle breakdown that can injure the kidneys). If you are on both, report any unexplained muscle pain, weakness, or dark urine to your doctor immediately.
How long does fenofibrate take to work?
Triglyceride levels typically begin to fall within the first few weeks of starting fenofibrate, with the full effect usually seen within 4–8 weeks. Your prescriber will likely check your lipid levels (a fasting blood test) after several weeks to assess the response and decide whether treatment should continue, be adjusted, or be combined with other therapies.
Does fenofibrate affect the kidneys?
Fenofibrate can cause a mild, reversible increase in serum creatinine — a lab marker of kidney function. For most patients this is not harmful, but it does mean regular kidney function monitoring is recommended. Fenofibrate is generally not recommended in people with significantly reduced kidney function (severe chronic kidney disease), and the apparent creatinine increase can sometimes make it difficult to accurately track true kidney health in people with pre-existing kidney disease.
Related Drugs
Other medications commonly used for high cholesterol or triglycerides: